David Hochman

Vivasure Medical Ltd. is an ISO 13485 registered medical device company based at Europe’s leading MedTech cluster in Galway, Ireland. Founded in 2009, the company is led by an experienced management team and backed by a syndicate of international venture capital investors and state agencies. The company has developed and patented the world’s first fully absorbable, patch-based closure device specifically designed to seal large-bore arteriotomies in endovascular procedures. Please, refer to our website for further information.

Corbus is a precision oncology company committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus’ internal development pipeline includes CRB-701, a next generation antibody drug conjugate (ADC) that targets the expression of Nectin 4-on cancer cells to release a cytotoxic payload and CRB-601, and anti-integrin monoclonal antibody which blocks the activation of TGFβ expressed on cancer cells. We are tenacious and will keep pushing the known boundaries to make breakthroughs where others have not.

FreeHold Surgical, Inc. is a privately held medical device company that is focused on development and commercialization of innovative technologies to advance laparoscopic and robotic procedures. Our first two products, FreeHold Duo™ and FreeHold Trio™ Hands-Free Intracorporeal Retractors became commercially available in the US in Q4 2014.

Motus GI Holdings, Inc. (NASDAQ: MOTS) is a medical technology company based in the U.S., with subsidiaries in the U.S. and Israel, dedicated to improving endoscopy outcomes, lowering costs and enhancing patient experiences. The Company is focused on the development and commercialization of the Pure-Vu® System, designed to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon. The Pure-Vu® System is a 510(k) U.S. Food and Drug Administration cleared medical device indicated to help facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure. The device integrates with standard colonoscopes to enable cleaning during the procedure while preserving standard procedural workflow and techniques. The Pure-Vu® System has received CE mark approval in Europe.

Vivasure Medical Ltd. is an ISO 13485 registered medical device company based at Europe’s leading MedTech cluster in Galway, Ireland. Founded in 2009, the company is led by an experienced management team and backed by a syndicate of international venture capital investors and state agencies. The company has developed and patented the world’s first fully absorbable, patch-based closure device specifically designed to seal large-bore arteriotomies in endovascular procedures. Please, refer to our website for further information.

Orchestra BioMed (Nasdaq: OBIO) is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies. Orchestra BioMed’s partnership-enabled business model focuses on forging strategic collaborations with leading medical device companies to drive successful global commercialization of products it develops. Under these collaborations, Orchestra BioMed advances its promising therapeutic solutions through late-stage clinical research and regulatory approvals, while its collaborators focus on leveraging their commercial expertise and existing infrastructure to bring these product candidates to global markets quickly and efficiently. Orchestra BioMed’s lead product candidate is atrioventricular interval modulation (AVIM) therapy (also known as BackBeat Cardiac Neuromodulation Therapy (CNT™)) for the treatment of hypertension, a significant risk factor for death worldwide. Orchestra BioMed is also developing Virtue® Sirolimus AngioInfusion™ Balloon (SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Orchestra BioMed has a strategic collaboration with Medtronic, one of the largest medical device companies in the world, for development and commercialization of AVIM therapy for the treatment of hypertension in pacemaker-indicated patients, and a strategic partnership with Terumo, a global leader in medical technology, for development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed has additional product candidates and plans to potentially expand its product pipeline through acquisitions, strategic collaborations, licensing and organic development. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com.

Corbus is a precision oncology company committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus’ internal development pipeline includes CRB-701, a next generation antibody drug conjugate (ADC) that targets the expression of Nectin 4-on cancer cells to release a cytotoxic payload and CRB-601, and anti-integrin monoclonal antibody which blocks the activation of TGFβ expressed on cancer cells. We are tenacious and will keep pushing the known boundaries to make breakthroughs where others have not.

FreeHold Surgical, Inc. is a privately held medical device company that is focused on development and commercialization of innovative technologies to advance laparoscopic and robotic procedures. Our first two products, FreeHold Duo™ and FreeHold Trio™ Hands-Free Intracorporeal Retractors became commercially available in the US in Q4 2014.